Glucagon-like peptide-1 receptor agonists may be new treatment for opioid and alcohol use disorder, finds study

Until now, most of the existing research into using GLP-1 RAs and GIPs to treat substance use disorders consists of animal studies and small-scale clinical trials.

This new large-scale human study looked at 503,747 people with a history of opioid use disorder (OUD), of which 8,103 had a prescription for a GLP-1 RA or GIP. The study found that people with OUD who had a GLP-1 RA or GIP prescription had a 40% lower rate of opioid overdose compared with those who did not have a prescription.

The study also looked at 817,309 people with a history of alcohol use disorder (AUD), of which 5,621 had a prescription for a GLP-1 RA or GIP. The study found that people with AUD who had a GLP-1 RA or GIP prescription had a 50% lower rate of alcohol intoxication compared with those who did not have a prescription.

This study may introduce a promising new treatment for substance use disorders.

Reference:

Fares Qeadan, Ashlie McCunn, Benjamin Tingey, The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis, Addiction, https://doi.org/10.1111/add.16679.